Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial
Camidge, R Kim, HR Ahn, MJ Yang, JCH Han, JY Hochmair, MJ Lee, KH Delmonte, A Campelo, MRG Kim, DW
Camidge, R
Kim, HR
Ahn, MJ
Yang, JCH
Han, JY
Hochmair, MJ
Lee, KH
Delmonte, A
Campelo, MRG
Kim, DW
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Camidge R, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. Annals of Oncology. 2019;30:ix195-ix6.